Bausch + Lomb Corporation (BLCO) Stock: Price, Forecast & Analyst Target
Bausch + Lomb Corporation (BLCO) — MoonshotScore 35/100 (Weak band), calculated Nov 22, 2026. Price $19.38 (-6.33%), as of the Nov 20, 2026 trading session; market cap $6.93B. Expected results Feb 17, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 13.51× (market value Nov 20, 2026; cash Sep 30, 2026) · expected results Feb 17, 2027
Bausch + Lomb Corporation · BLCO · NYSE · Healthcare · Medical - Instruments & Supplies
Research dated 2026-09-13: Bausch and Lomb operates across the full spectrum of eye care, manufacturing everything from daily contact lenses and over-the-counter drops to specialized surgical equipment. The investment case rests on whether the business can expand its pharmaceutical and surgical divisions rapidly enough to service a massive debt load while still funding necessary clinical research.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Bausch + Lomb (BLCO)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a fragile balance sheet — yet price is running hot, well ahead of those stalled fundamentals; treat the move with suspicion, not chase. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Strained; Valuation: Fair; Growth Durability: Growing; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- Altman Z 1.03 · Piotroski F 5
- ROE -1.7% · ROA -0.8% · current ratio 1.56 · earnings yield -1.5% · free-cash-flow yield 3.4%
Holding back: balance-sheet strain
Helping: business quality, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 35 | Weak | |
| 35 | Weak | |
| 35 | Weak | |
| 35 | Weak | |
| 35 | Weak | |
| 35 | Weak |
The score was 35 in the stored Nov 21, 2026 snapshot and remains 35 in the current publication computed Nov 22, 2026 (0); the largest pillar moves were Valuation +3 and Financial Safety +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $19.38 | |
| Change on the day | -6.33% | |
| 52-week range | $14.44–$21.40 | |
| Market capitalisation | $6.93B | |
| Shares traded on the day | 871.6K | |
| Beta (volatility vs the S&P 500) | 0.52 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We continue to expect interest expense of approximately $365 million and full year CapEx of approximately $285 million. We now expect the adjusted tax rate to be approximately 18%, slightly below our previous outlook of 19.0%.
Osama A. Eldessouky · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Bausch + Lomb (BLCO): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 22, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 22, 2026, except a card that shows its own read date.
What is Bausch + Lomb (BLCO), and what does it report?
Short answer · as of
While the industry classification groups the business with medical instruments suppliers, the enterprise actually operates distinct divisions under a unified corporate umbrella.
Research dated 2026-09-13.
The consumer segment functions like a traditional packaged goods operation, generating revenue through recurring retail purchases of contact lenses and eye drops.
In contrast, the surgical and pharmaceutical arms act as specialized medical technology developers. These divisions require continuous research spending to engineer advanced intraocular lenses, surgical machinery, and proprietary prescription medications for complex ocular diseases.
What do the latest results show for Bausch + Lomb (BLCO)?
Research dated 2026-09-13.
Recent financial reports show reliable revenue expansion, yet the bottom line remains mired in net losses. This persistent divergence stems from structural operating costs and debt obligations rather than any deficiency in consumer demand for eye care products.
Executives credit moderating currency exchange headwinds for preserving some top-line momentum. However, management also acknowledges that research and development spending must remain elevated as a share of total revenue to maintain a competitive product pipeline.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $1.38B Sep 30, 2026
- Latest quarter · R&D
- $91.00M Sep 30, 2026
- Latest quarter · SG&A
- $556.00M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $155.00M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $1.38B | $91.00M | $556.00M | $155.00M |
| Jun 30, 2026 | $1.39B | $114.00M | $588.00M | $83.00M |
| Mar 31, 2026 | $1.24B | $101.00M | $544.00M | $59.00M |
| Dec 31, 2025 | $1.41B | $94.00M | $564.00M | $158.00M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.38B Oct 28, 2026
- Latest report · revenue estimate
- $1.37B Oct 28, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 28, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 28, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 28, 2026 | $1.38B | $1.37B | $0.3400 | $0.2145 |
| Jul 29, 2026 | $1.39B | $1.37B | $0.1600 | $0.1544 |
| Apr 29, 2026 | $1.24B | $1.22B | $0.0800 | $0.0600 |
| Feb 18, 2026 | $1.41B | $1.39B | $0.3200 | $0.3500 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $1.28B | -$28M | -$0.08 (diluted) |
| Q4 FY2025 | $1.41B | -$58M | -$0.16 (diluted) |
| Q1 FY2026 | $1.24B | -$71M | -$0.20 (diluted) |
| Q2 FY2026 | $1.39B | -$14M | -$0.04 (diluted) |
What are the financial strengths and risks for Bausch + Lomb (BLCO)?
Short answer · as of
Cash and short-term investments were $513.00M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $233.00M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
The balance sheet presents the most acute risk to equity holders. Total liabilities thoroughly dwarf the available cash and short-term investments, creating a highly leveraged capital structure that restrains strategic flexibility.
While cash flow from core operations remains positive and comfortably covers routine capital expenditures, the sheer scale of the corporate debt demands constant attention. This leverage leaves the enterprise vulnerable to elevated borrowing costs or any sudden contraction in consumer spending on premium health products.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 1.03 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-1.7%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $233.00M Sep 30, 2026
- Previous quarter · operating cash flow
- $153.00M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $233.00M | −$55.00M |
| Jun 30, 2026 | $153.00M | −$71.00M |
| Mar 31, 2026 | $32.00M | −$100.00M |
| Dec 31, 2025 | $134.34M | −$72.54M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Bausch + Lomb (BLCO)?
Short answer · as of
The next earnings report is expected on Feb 17, 2027.
Research dated 2026-09-13.
The upcoming earnings disclosure will test whether the company can maintain its historically consistent pattern of surpassing consensus revenue estimates. Market observers will monitor operating margins closely to see if the promised stability in gross profitability actually materializes amidst fluctuating global currency dynamics.
Any unannounced reduction in research spending or capital expenditures would signal a shift toward urgent cash preservation. Conversely, sustained investment levels would confirm management confidence in the current liquidity position and the broader product pipeline.
What management is planning
How does Bausch + Lomb compare with its peers?
Short answer
Bausch + Lomb's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Unlike pure pharmaceutical developers or narrowly focused surgical device makers, this enterprise bundles specialized medical technology with high-volume retail consumer goods. This structural integration creates a distinct revenue buffer.
Because the portfolio spans from basic saline solutions to complex surgical equipment, an unexpected setback in clinical drug trials or regulatory device approvals can be partially cushioned by steady, recurring sales of everyday contact lenses and over-the-counter allergy drops.
| Company | Price | Market value | Score |
|---|---|---|---|
| $63.34 Nov 20, 2026 | $9.57B | 92 5-pillar Nov 22, 2026 | |
| $120.16 Nov 20, 2026 | $5.47B | 82 5-pillar Nov 22, 2026 | |
| $84.34 Nov 20, 2026 | $5.05B | 82 5-pillar Nov 22, 2026 | |
| $140.08 Nov 20, 2026 | $8.88B | 78 5-pillar Nov 22, 2026 | |
| $172.52 Nov 20, 2026 | $4.31B | 74 5-pillar Nov 22, 2026 | |
| $15.65 Nov 20, 2026 | $4.27B | 74 5-pillar Nov 22, 2026 | |
| $14.84 Nov 20, 2026 | $10.1B | 71 5-pillar Nov 22, 2026 | |
| $163.81 Nov 20, 2026 | $10.5B | 71 5-pillar Nov 22, 2026 | |
| $161.58 Nov 20, 2026 | $6.41B | 62 5-pillar Nov 22, 2026 | |
| $25.39 Nov 20, 2026 | $13.1B | 58 5-pillar Nov 22, 2026 | |
| $55.39 Nov 20, 2026 | $8.77B | 51 5-pillar Nov 22, 2026 | |
| $58.88 Nov 20, 2026 | $11.2B | 40 5-pillar Nov 22, 2026 | |
| Bausch + Lomb (BLCO) — this page | $19.38 | $6.93B | 35 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $17.00 – $24.00
- Consensus target
- $21.75
- Median target
- $22.50
Consensus record · Captured .
Measured against a quoted price of $19.38 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 29, 2026
- Transactions
- 32
- Identified insiders
- 19
- Purchases
- 0
- Sales
- 4
- Other transactions
- 28
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 10.4% Period end Sep 30, 2026
- Previous quarter · ownership
- 10.7% Prior to period end Sep 30, 2026
- Reporting holders
- 107 Period end Sep 30, 2026
- Previous quarter · holders
- 102 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Brookfield Corp /On/ | 4,565,719 |
| D. E. Shaw & Co., INC. | 3,379,704 |
| Deutsche Bank AG\ | 3,329,257 |
| Davidson Kempner Capital Management LP | 3,158,972 |
| Goldentree Asset Management LP | 3,106,987 |
Tracked investors
Which of the 16 named investors we follow held BLCO in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Icahn Capital | Carl Icahn | Q3 2026 | 0.43% | $40.43M | Trimmed −32.1% shares |
| Third Point | Dan Loeb | Q3 2026 | 0.03% | $1.45M | Held, unchanged |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Bausch + Lomb (BLCO)?
Common Questions About BLCO (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What drives revenue in the surgical segment?
The surgical division generates income by supplying the machinery and specialized tools required for complex procedures like cataract removals and retinal treatments. Growth here relies on medical facilities continually upgrading their phacoemulsification equipment and purchasing proprietary intraocular lenses for their patients.
How do currency fluctuations affect the business?
Because the company manufactures and distributes products globally, varying exchange rates can significantly alter reported revenue. Management recently noted that stabilizing foreign exchange conditions are providing a modest tailwind, slightly easing the pressure on overall profitability.
Why does the company report consistent net losses despite growing sales?
Strong consumer demand for eye care products drives healthy revenue, but the resulting gross profit is consumed by structural overhead, continuous research funding, and significant debt service obligations. Until operating margins expand or the debt burden shrinks, the enterprise will likely continue prioritizing operating cash flow over strict accounting profitability.
Does the consumer health division offer anything besides contact lenses?
The consumer portfolio extends well beyond basic corrective lenses to include comprehensive lens care solutions, over-the-counter diagnostic drops, and specialized nutritional supplements. These retail products target widespread, chronic conditions like ocular allergies and dry eye, creating a reliable stream of repeat purchases.
What is the BLCO stock price today?
The last price recorded for Bausch + Lomb Corporation (BLCO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BLCO price target?
The analyst consensus price target for Bausch + Lomb Corporation (BLCO), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 81 figures on this page — 2 from SEC filings and earnings calls, 72 from Financial Modeling Prep (FMP), 2 with no recorded source, 3 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com